This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Merck & Co., Inc.
Drug Names(s): IDX375
Description: IDX375 is a non-nucleoside polymerase inhibitor. Preclinical testing demonstrated that IDX375 targets the palm non-nucleoside pocket of HCV polymerase. IDX375 exhibited single nanomolar in vitro potency against HCV genotype 1b replicon (EC50 = 2 nM) and against HCV genotype 1a and 1b polymerases. Additionally, cellular cytotoxicity testing in Huh-7 cells demonstrated that IDX375 is not cytotoxic (CC50 >100 µM), resulting in a selectivity index >33,000 for IDX375. In preclinical in vitro studies, IDX375 did not inhibit human cellular DNA polymerases a, ß and v (IC50 >100 µM), demonstrating selectivity for the HCV 1a and 1b polymerases. Based on favorable preclinical pharmacokinetics, IDX375 has the potential for once- or twice-daily dosing in man.
In May 2003, Novartis purchased 54% of the common stock of Idenix. Pursuant to the development and commercialization agreement, Idenix granted Novartis the option to license any of its development-stage drug candidates, so long as Novartis maintains at least 30% ownership of Idenix's common stock.
Merck and Idenix
In June 2014, Merck and Idenix announced that the companies have entered into a definitive agreement under which Merck will acquire Idenix.
In August 2014, Merck announced the successful completion of the tender offer for all of the outstanding shares of common stock of Idenix.
Additional information available to subscribers only: